Finanzwire Finanzwire
Basculer en Français
11083 Companies
243279 Keywords
171456 Articles
131016 Press releases
Headlines Articles Press releases Ascend Advanced Therapies (Ascend) Remove
  1. Home
  2. Companies
  3. Ascend Advanced Therapies (Ascend)
Finanzwire
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 11/10/2025 at 18:10, 10 months 15 days ago

    Ascend's Innovation Enhances AAV Production Efficiency

    Gene Therapy Biotechnology Innovation Ascend Advanced Therapies AAV Production Manufacturing Enhancers
  • PRESS RELEASE

    published on 11/10/2025 at 18:05, 10 months 15 days ago

    Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields Without Compromising Quality

    Ascend Advanced Therapies unveils proprietary enhancers demonstrating significant improvements in AAV yields and quality attributes for gene therapy programs
    Ascend Advanced Therapies Proprietary Enhancers AAV Yields Gene Therapy Programs Quality Attributes
    Logo of Ascend Advanced Therapies (Ascend)
  • BRIEF

    published on 10/08/2025 at 15:10, 11 months 17 days ago

    Ascend Advanced Therapies Successfully Defends EpyQ® Patent at EPO

    Intellectual Property Gene Therapy European Patent Office Ascend Advanced Therapies EpyQ® AAV Plasmid
  • PRESS RELEASE

    published on 10/08/2025 at 15:05, 11 months 17 days ago

    European Patent on Ascend Advanced Therapies' EpyQ® AAV Plasmid Technology Successfully Defended at the EPO

    Ascend Advanced Therapies successfully defends European patent EP3722434 for EpyQ® AAV plasmid technology at the EPO, reinforcing its position in gene therapy
    Gene Therapy European Patent Ascend Advanced Therapies EpyQ® AAV Plasmid Technology
    Logo of Ascend Advanced Therapies (Ascend)
Accesswire
  • Published on 09/26/2026 at 01:00, 12 hours 47 minutes ago

    Guanajuato Silver Renews Base Shelf Prospectus

  • Published on 09/26/2026 at 01:00, 12 hours 47 minutes ago

    Findev Inc. Provides Update on Victoria Park Loan Exposure and Expected Accounting Impairment

  • Published on 09/25/2026 at 22:15, 15 hours 32 minutes ago

    Rocky Shore Gold Closes First Tranche of Non-Brokered Private Placement

  • Published on 09/25/2026 at 17:30, 20 hours 17 minutes ago

    Goldcliff Announces Unit and Flow Through "LIFE" Offerings

  • Published on 09/25/2026 at 15:00, 22 hours 47 minutes ago

    HM Exploration Provides Program Update for the Lewis Pilley's Project

View all ACCESSWIRE
EQS Group
  • Published on 09/26/2026 at 07:45, 6 hours 2 minutes ago

    Green SM Begins Pilot Operations In The Netherlands, Further Expanding Its Presence In Europe

  • Published on 09/26/2026 at 00:01, 13 hours 46 minutes ago

    Photon Energy N.V. Sells 7.6 MWp of PV Operational Assets in Slovakia

  • Published on 09/25/2026 at 18:30, 19 hours 17 minutes ago

    029 Group SE: Publication of Half-Year Report 2026

  • Published on 09/25/2026 at 18:15, 19 hours 32 minutes ago

    Warren Wise decodes Qiagen’s DNA

  • Published on 09/25/2026 at 17:30, 20 hours 17 minutes ago

    GEVELOT S.A.: Weekly declaration of share buybacks – 09/25/2026 (French only)

View all EQS
Les Echos
  • Published on 09/25/2026 at 17:40, 20 hours 7 minutes ago

    Availability of the 2026 half-year financial report

  • Published on 09/24/2026 at 18:10, 1 day 19 hours ago

    Financial statements - 30 june 2026

  • Published on 09/24/2026 at 18:00, 1 day 19 hours ago

    GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026

  • Published on 09/24/2026 at 18:00, 1 day 19 hours ago

    GUILLEMOT CORPORATION: 2026 CONSOLIDATED INTERIM RESULTS

  • Published on 09/24/2026 at 17:45, 1 day 20 hours ago

    Cegedim first-half 2026 results: profitability continues to improve

View all LES ECHOS COMFI WIRE

With finanzwire.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

Finanzwire

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

© 2026 Finanzwire

Contact Authors Cookies policy Terms and conditions Privacy policy